• (-)-Arctigenin: Translating MEK1/NF-κB Dual Modulation to On

  2026-05-27

  This article explores the translational impact of (-)-Arctigenin, a high-purity MEK1 inhibitor and NF-κB pathway modulator, in the context of breast cancer metastasis. Drawing on mechanistic insights, preclinical evidence, and strategic workflow guidance, we challenge traditional product write-ups by connecting molecular detail to actionable research design. Special emphasis is placed on the interplay between tumor microenvironment, extracellular vesicle signaling, and the clinical imperative for anti-inflammatory agents targeting metastatic progression.

• Machine Learning-Guided Prediction of LNPs for mRNA Vaccines

  2026-05-27

  This study pioneers a machine learning approach for predicting effective lipid nanoparticle (LNP) formulations for mRNA vaccine delivery, significantly accelerating the optimization process. The model identifies crucial ionizable lipid substructures—validated experimentally with Dlin-MC3-DMA—offering a robust framework for rational LNP design in nucleic acid therapeutics.

• Machine Learning-Driven LNPs for Microglia-Targeted mRNA Del

  2026-05-26

  This study demonstrates the application of machine learning to optimize immunomodulatory lipid nanoparticles (LNPs) for efficient mRNA delivery to hyperactivated microglia. The findings reveal that ML-guided LNP engineering, particularly with hyaluronic acid modifications, can effectively repolarize inflammatory microglial phenotypes, advancing strategies for neuroinflammatory disease intervention.

• Ibotenic Acid: Rigorous Toxicology and Best Practices in Neu

  2026-05-26

  Explore the latest insights into ibotenic acid as an NMDA receptor agonist, focusing on its in vivo toxicity profile and optimized protocols for disease modeling. This article delivers a research-driven guide to harnessing ibotenic acid’s unique properties for reproducible neuroscience applications.

• N6-Methyl-dATP: Unveiling Mechanistic Insights for Epigeneti

  2026-05-25

  Explore the mechanistic impact of N6-Methyl-dATP on DNA replication fidelity and genomic stability. This article uniquely bridges molecular function, assay design, and translational potential, offering researchers actionable insights beyond standard protocols.

• DiR (DiIC 18 (7)): Optimizing Live and Fixed Cell Membrane S

  2026-05-25

  DiR (DiIC 18 (7)) empowers translational researchers with long-term, high-sensitivity membrane labeling for cell tracking, neuronal tracing, and extracellular vesicle workflows. Recent advances in 'Engage & Evasion' strategies, as showcased in the reference study, position this probe as a cornerstone for overcoming mononuclear phagocyte system barriers and maximizing therapeutic EV distribution.

• Technical Guide to HyperScribe™ T7 High Yield Cy3 RNA Labeli

  2026-05-24

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus enables efficient and reproducible synthesis of Cy3-labeled RNA probes for applications such as in situ hybridization and Northern blotting. It addresses the challenge of achieving high-yield, fluorescently labeled RNA without compromising transcription efficiency. This kit is intended exclusively for research workflows and is not validated for diagnostic or therapeutic use.

• Phosbind Acrylamide: Advancing Translational Phosphorylation

  2026-05-23

  Explore how Phos binding reagent (Phosbind) acrylamide enables antibody-free, mechanistically precise protein phosphorylation analysis, integrating the latest insights from neuronal signaling research. Designed for translational scientists, this article bridges mechanistic understanding with strategic guidance, highlights protocol innovations, and positions APExBIO's solution as a catalyst for impactful signaling pathway discoveries.

• β-Catenin/BCL9 Inhibition Sensitizes Tumors to Immunotherapy

  2026-05-22

  Feng et al. (2019) demonstrate that disrupting the β-catenin/BCL9 interaction overcomes immune checkpoint blockade resistance by modulating regulatory T cells within the tumor microenvironment. Their hydrocarbon-stapled peptide inhibitors represent a promising, experimentally validated strategy to enhance immunotherapy efficacy in solid tumor models.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Practical Workflow

  2026-05-22

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides reliable, fluorescence-based detection of goat IgG primaries in immunofluorescence, IHC, ELISA, and flow cytometry assays. It is not suitable for non-goat primaries or non-immunoglobulin targets, and its use should be limited to validated immunodetection workflows to ensure accurate results.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Technical Use Guide

  2026-05-21

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody enables sensitive, specific detection of goat immunoglobulins in ICC/IF, IHC, flow cytometry, and ELISA workflows by providing robust fluorescence-based signal amplification. It should only be applied in contexts where a goat primary antibody is used, and is not validated for detection of non-goat primaries or for use outside the specified immunodetection assays.

• Sulfaphenazole: A Precision CYP2C9 Inhibitor for Vascular Re

  2026-05-21

  Sulfaphenazole stands out as a potent, selective CYP2C9 inhibitor uniquely suited for dissecting cytochrome P450-mediated metabolism and vascular endpoints. Its dual action as an antibacterial and vascular-protective agent enables high-impact translational workflows, from endothelial function assays to ischemia-reperfusion injury models.

• Aclacinomycin A: Mechanisms, Cytotoxicity, and Research Para

  2026-05-20

  Aclacinomycin A (Aclarubicin) is an anthracycline used as a dual topoisomerase inhibitor and apoptosis inducer. Its cytotoxicity is quantifiable in major cancer cell lines, with well-documented molecular mechanisms and protocol benchmarks.

• Sulfaphenazole: Unveiling New Frontiers in Endothelial Resea

  2026-05-20

  Explore Sulfaphenazole as a gold-standard CYP2C9 inhibitor and its unique role in restoring vascular endothelial function and reducing oxidative stress. This article delivers advanced scientific insights, directly linking mechanistic findings to practical assay design.

• Syringin Targets EGFR/PI3K/Akt to Enhance Sunitinib in RCC M

  2026-05-19

  This study demonstrates that Syringin, a phenylpropanoid glycoside, inhibits renal cell carcinoma cell proliferation and overcomes sunitinib resistance by modulating the EGFR/PI3K/Akt pathway. The findings highlight new strategies for bioactive compound screening and natural product research in drug-resistant RCC.

16220 records 1/1082 page Next 12345 下5页 Last page